Study on the luminescence behavior of sulfobutylether-β-cyclodextrin with risperidone and its analytical application

Abstract

The interaction of sulfobutylether-β-cyclodextrin (SBE-β-CD) with risperidone (RISP) was first described with luminol–SBE-β-CD chemiluminescence (CL) system by flow injection analysis (FIA). In luminol–SBE-β-CD CL system, the 1:1 SBE-β-CD⋯luminol∗ complexation could enhance CL intensity of luminol and produce the effect of complexation enhancement of CL (CEC). It was found that RISP could quench the CL intensity of SBE-β-CD⋯luminol∗ and caused the effect of complexation enhancement of quenching (CEQ), the formation constant KR-CD 3.4×104Lmol−1 and the stoichiometric ratio 1:1 of RISP⋯SBE-β-CD complex were obtained by the proposed CL model. Association degree α 0.036 of RISP⋯SBE-β-CD complex was also given by CL method. Based on the linear relationship to the decrement of luminol–SBE-β-CD–RISP CL intensity and the logarithm of RISP concentration, RISP also can be quantified in the linear range of 3.0–500.0nmolL−1 with a detection limit of 1.0nmolL−1 (3σ). The proposed method was successfully applied to monitoring excreted RISP in human urine. It was found that RISP reached its maximum after oral administration for 1.5h with the total excretion of 14.26% within 8.5h; the elimination rate constant k and half-life time t1/2 were 0.474 and 1.5h, respectively.